Chen Hubert
College of Arts and Science, Vanderbilt University, Nashville, TN, United States.
Front Genet. 2025 Jul 15;16:1550723. doi: 10.3389/fgene.2025.1550723. eCollection 2025.
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, predominantly occurring in patients with underlying chronic liver disease, including cirrhosis. Organic anion transporter polypeptides (OATPs), encoded by SLCO genes, are one of the most important SLC subfamilies involved in the cellular uptake of drugs and endobiotic. OATP1B1 (SLCO1B1 gene), OATP1B3 (SLCO1B3 gene), and OATP2B1 (SLCO2B1 gene) are hepatic uptake transporters highly expressed in the liver. We aimed to systematically analyze expression levels of SLCO1B1, SLCO1B3, and SLCO2B1 and to investigate their prognostic role in predicting HCC clinical outcomes using open-source databases.
A comparison of HCC and matched normal tissue gene and protein expression was performed using the TCGA and CPTAC datasets through UALCAN. The correlation between SLCO gene and protein expression with patient survival was evaluated using OncoLnc, KM-Plotter, and OSppc. SLCO genetic alterations in HCC were explored using cBioPortal. A protein-protein interaction map for SLCO1B1, SLCO1B3, and SLCO2B1 was also constructed using STRING.
Gene and protein expression levels of SLCO1B1, SLCO1B3, and SLCO2B1 were significantly downregulated in HCC patients compared to normal counterparts. Clinically, the low gene expression of SLCO1B1, SLCO1B3, and SLCO2B1 was correlated with shorter survival rate in HCC patients. Kaplan-Meier analysis further confirmed that low protein levels of these transporters predicted poor prognosis for HCC patients. Analysis of the TCGA Liver Hepatocellular Carcinoma dataset (Cance Atlas) revealed a low mutation and amplification frequency in HCC for SLCO1B1 (0.57% vs. 0.29%), SLCO1B3 (0.86% vs. 0.29%), and SLCO2B1 (0.57% vs. 0.86%), respectively. Network analysis highlighted non-random interconnectivity among SLCO1B1, SLCO1B3, and SLCO2B1.
SLCO1B1, SLCO1B3, and SLCO2B1 are highly expressed in the and play key roles in many liver diseases. In , the downregulation of SLCO1B1, SLCO1B3, and SLCO2B1 expression has been observed. SLCO genes such as SLCO1B1, SLCO1B3, and SLCO2B1 expression levels may also serve as prognostic predictive markers in HCC patients.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,主要发生于患有包括肝硬化在内的潜在慢性肝病的患者中。由SLCO基因编码的有机阴离子转运多肽(OATP)是参与药物和内源性物质细胞摄取的最重要的溶质载体(SLC)亚家族之一。OATP1B1(SLCO1B1基因)、OATP1B3(SLCO1B3基因)和OATP2B1(SLCO2B1基因)是在肝脏中高度表达的肝脏摄取转运体。我们旨在使用开源数据库系统分析SLCO1B1、SLCO1B3和SLCO2B1的表达水平,并研究它们在预测HCC临床结局中的预后作用。
通过UALCAN使用TCGA和CPTAC数据集对HCC及配对的正常组织基因和蛋白质表达进行比较。使用OncoLnc、KM-Plotter和OSppc评估SLCO基因和蛋白质表达与患者生存之间的相关性。使用cBioPortal探索HCC中的SLCO基因改变。还使用STRING构建了SLCO1B1、SLCO1B3和SLCO2B1的蛋白质-蛋白质相互作用图谱。
与正常对照相比,HCC患者中SLCO1B1、SLCO1B3和SLCO2B1的基因和蛋白质表达水平显著下调。临床上,SLCO1B1、SLCO1B3和SLCO2B1的低基因表达与HCC患者较短的生存率相关。Kaplan-Meier分析进一步证实,这些转运体的低蛋白水平预示着HCC患者预后不良。对TCGA肝细胞癌数据集(癌症图谱)的分析显示,HCC中SLCO1B1(0.57%对0.29%)、SLCO1B3(0.86%对0.29%)和SLCO2B1(0.57%对0.86%)的突变和扩增频率较低。网络分析突出了SLCO1B1、SLCO1B3和SLCO2B1之间的非随机互连性。
SLCO1B1、SLCO1B3和SLCO2B1在[此处原文缺失具体内容]中高度表达,并在许多肝脏疾病中起关键作用。在[此处原文缺失具体内容]中,已观察到SLCO1B1、SLCO1B3和SLCO2B1表达下调。SLCO1B1、SLCO1B3和SLCO2B1等SLCO基因的表达水平也可能作为HCC患者的预后预测标志物。